Mark H. Knapp
Impact in
-
- Lymphoma Diagnosis and Treatment
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 11
- Biomedical Research and Pathophysiology 1
- Genetics 7
- Chronic Lymphocytic Leukemia Research 7
- Co-authors
- Andre Henri Goy (5 shared papers)Jutta Katrin Neuenburg (5 shared papers)Darrin M. Beaupre (5 shared papers)Sven de Vos (6 shared papers)Jerry Ping (3 shared papers)Radhakrishnan Ramchandren (2 shared papers)Nilanjan Ghosh (2 shared papers)Edwin C. Kingsley (2 shared papers)
- Journals
- Blood (9 papers)Journal of Clinical Oncology (3 papers)Journal of Thoracic Oncology (1 paper)Cancer Investigation (1 paper)Archives of Pathology & Laboratory Medicine (1 paper)
- Partner nations
- United StatesChinaSaudi Arabia
In The Last Decade
Mark H. Knapp
17 papers receiving 539 citations
Mark H. Knapp's Hit Papers
Peers
Comparison fields: 5 of 41
- Pathology and Forensic Medicine 275
- Genetics 136
- Oncology 237
- Pulmonary and Respiratory Medicine 129
- Cancer Research 48
Countries citing papers authored by Mark H. Knapp
This map shows the geographic impact of Mark H. Knapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark H. Knapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark H. Knapp more than expected).
Fields of papers citing papers by Mark H. Knapp
This network shows the impact of papers produced by Mark H. Knapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark H. Knapp. The network helps show where Mark H. Knapp may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark H. Knapp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 111 | |
| 2 | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Hit paper breakdown → | 2024 | 97 |
| 3 | 2009 | 83 | |
| 4 | 2019 | 67 | |
| 5 | 2015 | 28 | |
| 6 | 2002 | 26 | |
| 7 | 2020 | 24 | |
| 8 | 2008 | 24 | |
| 9 | 2005 | 16 | |
| 10 | 2016 | 14 | |
| 11 | 2014 | 13 | |
| 12 | 2009 | 12 | |
| 13 | 2006 | 11 | |
| 14 | 2015 | 8 | |
| 15 | 2016 | 7 | |
| 16 | 2016 | 6 | |
| 17 | 2016 | 6 |
About Mark H. Knapp
Mark H. Knapp is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 17 papers that have together received 553 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (7 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Cancer Immunotherapy and Biomarkers (1 paper), Bladder and Urothelial Cancer Treatments (1 paper), Chronic Myeloid Leukemia Treatments (1 paper) and Biomedical Research and Pathophysiology (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (275 citations), Genetics (136 citations), Oncology (237 citations), Pulmonary and Respiratory Medicine (129 citations) and Cancer Research (48 citations). Mark H. Knapp has collaborated with scholars based in United States, China and Saudi Arabia. Frequent co-authors include Andre Henri Goy, Jutta Katrin Neuenburg, Darrin M. Beaupre, Sven de Vos, Jerry Ping, Radhakrishnan Ramchandren, Nilanjan Ghosh, Edwin C. Kingsley, Maria L. Delioukina and Nam Hoang Dang. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer Investigation and Archives of Pathology & Laboratory Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.